Vertex, with new launches gaining steam, boosts revenue forecast despite Trikafta dilemma in Russia
Despite positive early signs for its newly launched drugs Alyftrek and Journavx, Vertex's first-quarter sales missed analyst estimates partly due to an unauthorized Trikafta generic eating away at sales in Russia.
Despite positive early signs for its newly launched drugs Alyftrek and Journavx, Vertex's first-quarter sales missed analyst estimates partly due to an unauthorized Trikafta generic eating away at sales in Russia.
